Anti tumor compositions and methods of use

Abstract

An anti-cancer composition having biocompatible materials, which can selectively exploit chemical variations between normal cells and cancer cells to inhibit or prevent the proliferation of cancerous cells and methods of use.

1 . A chemical composition for use as a pharmaceutical for treating cancer, cell proliferating diseases, solid tumors, liquid tumors, myelodysplasia disorders, hyper proliferative disorders, plasma cell dyscrasias and metastatic diseases in a patient comprising: a core of at least a biologically acceptable copper compound, wherein said copper compound is a fixed copper compound and a sheath, a shell, a polymeric shell, a cover, a casing, an encoating, a jacket or combination thereof that encapsulates the biologically acceptable copper compound, said sheath, shell, polymeric shell, cover, casing, encoating, jacket or combination thereof being made of a material targeting cancer cells, cell proliferating disease cells, solid tumor cells, liquid tumor cells, myelodysplasia cells, hyper proliferative disorder cells, plasma cell dyscrasias cells or metastatic disease cells, and preventing immediate chemical interaction of the core with the surrounding environment and a pharmaceutically acceptable carrier. 
     
     
         2 . The chemical composition of  claim 1 , wherein the sheath is formed of a material selected from the group consisting essentially of lipids, polypeptides, oligopeptides, polynucleotides, proteins, liposomes and combinations thereof. 
     
     
         3 . The chemical composition of  claim 1 , wherein the sheath is formed of a material selected from the group consisting essentially of a glucose, a saccharide, a polysaccharide, a dextran, liposomes, derivatives and combinations thereof. 
     
     
         4 . The chemical composition of  claims 2  or  3 , wherein a liposome coat encapsulates the sheath. 
     
     
         5 . The chemical composition of  claim 4 , wherein a polysaccharide sheath encapsulates the composition. 
     
     
         6 . The chemical composition of  claim 1 , wherein the biologically acceptable copper compound is copper hydroxide. 
     
     
         7 . The chemical composition of  claim 1 , wherein the biologically acceptable copper compound is copper oxide. 
     
     
         8 . The chemical composition of  claim 1 , wherein the biologically acceptable copper compound is copper oxychloride. 
     
     
         9 . The chemical composition of  claim 1 , wherein the biologically acceptable copper compound is copper carbonate basic. 
     
     
         10 . The chemical composition of  claim 1 , wherein the biologically acceptable copper compound is copper-iron hydroxide. 
     
     
         11 . The chemical composition of  claim 1 , wherein the biologically acceptable copper compound is copper-iron oxide. 
     
     
         12 . The chemical composition of  claim 1 , wherein the biologically acceptable copper compound is copper-iron oxyhydroxide. 
     
     
         13 . A chemical composition for use in treating cancer, cell proliferating diseases, solid tumors, liquid tumors, myelodysplasia disorders, hyper proliferative disorders, plasma cell dyscrasias and metastatic diseases in a patient comprising: a core of at least a biologically acceptable copper compound and a biocompatible iron compound, wherein said copper compound is a fixed copper compound, and a sheath, a shell, a polymeric shell, a cover, a casing, an encoating, a jacket or combination thereof that encapsulates the biologically acceptable copper compound and the biocompatible iron compound, said sheath, shell, polymeric shell, cover, casing, encoating, jacket or combination thereof being made of a material targeting cancer cells, cell proliferating disease cells, solid tumor cells, liquid tumor cells, myelodysplasia cells, hyper proliferative disorder cells, plasma cell dyscrasias cells or metastatic disease cells, and preventing immediate chemical interaction of the core with the surrounding environment and a pharmaceutically acceptable carrier. 
     
     
         14 . The chemical composition of  claim 13 , wherein the sheath is formed of a material selected from the group consisting essentially of a glucose, a saccharide, a polysaccharide, a dextran, liposomes, derivatives and combinations thereof. 
     
     
         15 . The chemical composition of  claim 13 , wherein the sheath is formed of a material selected from the group consisting essentially of lipids, polypeptides, oligopeptides, polynucleotides, proteins, and combinations thereof. 
     
     
         16 . The chemical composition of  claims 14  or  15 , wherein a liposome coat encapsulates the sheath. 
     
     
         17 . The chemical composition of  claim 13 , wherein the copper-iron compound core is copper hydroxide-iron hydroxide. 
     
     
         18 . The chemical composition of  claim 13 , wherein said copper-iron compound core is copper hydroxide-iron oxide. 
     
     
         19 . The chemical composition of  claim 13 , wherein said copper-iron compound core is copper-iron oxyhydroxide. 
     
     
         20 . A pharmaceutical composition that targets cancerous cells, cell proliferating diseases, solid tumors, liquid tumors, myelodysplasia disorders, hyper proliferative disorders, plasma cell dyscrasias and metastatic diseases in a patient comprising: a core of at least a biologically acceptable copper compound; wherein said copper compound is a fixed copper compound, a sheath, a shell, a polymeric shell, a cover, a casing, an encoating, a jacket or combination thereof that encapsulates the biologically acceptable copper compound, said sheath, shell, polymeric shell, cover, casing, encoating, jacket or combination thereof being made of a material targeting cancer cells, cell proliferating disease cells, solid tumor cells, liquid tumor cells, myelodysplasia cells, hyper proliferative disorder cells, plasma cell dyscrasias cells or metastatic disease cells, and preventing immediate chemical interaction of the core with the surrounding environment and a pharmaceutically acceptable carrier. 
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein the fixed copper compound core is formed essentially of copper hydroxide. 
     
     
         22 . The pharmaceutical composition of  claim 20 , wherein the fixed copper compound core is formed essentially of copper oxide. 
     
     
         23 . The pharmaceutical composition of  claim 20 , wherein the fixed copper compound core is formed essentially of copper-iron hydroxide. 
     
     
         24 . The pharmaceutical composition of  claim 20 , wherein the fixed copper compound core is formed essentially of copper hydroxide-iron hydroxide. 
     
     
         25 . The pharmaceutical composition of  claim 20 , wherein the fixed copper compound core is formed essentially of copper hydroxide-iron oxyhydroxide. 
     
     
         26 . The pharmaceutical composition of  claim 20 , wherein the sheath is formed essentially of dextran. 
     
     
         27 . The pharmaceutical composition of  claim 20 , wherein the pharmaceutically acceptable carrier is a sterile aqueous carrier. 
     
     
         28 . A chemical composition for treating cancer cells and cell proliferating diseases, solid tumors, liquid tumors, myelodysplasia disorders, hyper proliferative disorders, plasma cell dyscrasias and metastatic diseases in mammals comprising: a compound of synergistic components of a core of at least a copper compound and a biocompatible iron compound, wherein said copper compound is a fixed copper compound and a pharmaceutically acceptable carrier. 
     
     
         29 . A chemical composition of  claim 28 , wherein the copper of the core particle is a fixed copper. 
     
     
         30 . A chemical composition of  claim 28 , wherein the copper of the core particle is copper hydroxide. 
     
     
         31 . A chemical composition of  claim 28 , wherein the iron of the core particle is iron hydroxide. 
     
     
         32 . A chemical composition of  claim 28 , wherein the iron of the core particle is iron oxide. 
     
     
         33 . A chemical composition of  claim 28 , wherein the iron of the core particle is an iron compound. 
     
     
         34 . A chemical composition of  claim 28 , wherein the core particle is encapsulated with a sheath. 
     
     
         35 . A chemical composition of  claim 28 , wherein the core particle is coated with liposomes. 
     
     
         36 . A chemical composition of  claim 28 , wherein the core particle is targeted with a targeting agent. 
     
     
         37 . A chemical composition of  claim 28 , wherein the core particle is targeted with a marker. 
     
     
         38 . A chemical composition of  claim 28 , wherein the core particle is targeted with magnetic particles. 
     
     
         39 . A chemical composition for use as a pharmaceutical for treating cancer, cell proliferating diseases, solid tumors, liquid tumors, myelodysplasia disorders, hyper proliferative disorders, plasma cell dyscrasias and metastatic diseases in a patient comprising: a core of at least a copper compound, wherein said copper compound is a fixed copper compound, and a sheath, a shell, a polymeric shell, a cover, a casing, an encoating, a jacket or combination thereof that encapsulates the biologically acceptable copper compound, said sheath, shell, polymeric shell, cover, casing, encoating, jacket or combination thereof being made of a material targeting cancer cells, cell proliferating disease cells, solid tumor cells, liquid tumor cells, myelodysplasia cells, hyper proliferative disorder cells, plasma cell dyscrasias cells or metastatic disease cells, and preventing immediate chemical interaction of the core with the surrounding environment and a pharmaceutically acceptable carrier. 
     
     
         40 . The chemical composition of  claim 39 , wherein the sheath is formed of a material selected from the group consisting essentially of lipids, polypeptides, oligopeptides, polynucleotides, proteins, liposomes and combinations thereof. 
     
     
         41 . The chemical composition of  claim 39 , wherein the sheath is formed of a material selected from the group consisting essentially of a glucose, a saccharide, a polysaccharide, a dextran, liposomes, derivatives and combinations thereof. 
     
     
         42 . The chemical composition of  claims 40  or  41 , wherein a liposome coat encapsulates the sheath. 
     
     
         43 . The chemical composition of  claim 42 , wherein a polysaccharide sheath encapsulates the composition. 
     
     
         44 . The chemical composition of  claim 39 , wherein the copper compound is copper hydroxide. 
     
     
         45 . The chemical composition of  claim 39 , wherein the copper compound is copper oxide. 
     
     
         46 . The chemical composition of  claim 39 , wherein the copper compound is copper oxychloride. 
     
     
         47 . The chemical composition of  claim 39 , wherein the copper compound is copper carbonate basic. 
     
     
         48 . The chemical composition of  claim 39 , wherein the copper compound is copper-iron hydroxide. 
     
     
         49 . The chemical composition of  claim 39 , wherein the copper compound is copper-iron oxide. 
     
     
         50 . The chemical composition of  claim 39 , wherein the copper compound is copper-iron oxyhydroxide.